{
    "clinical_study": {
        "@rank": "77057", 
        "arm_group": [
            {
                "arm_group_label": "PF-05402536", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PF-06413367", 
                "arm_group_type": "Experimental", 
                "description": "Intramuscular, multiple dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intramuscular"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and tolerability of multiple doses of\n      PF-05402536 and PF-06413367 in healthy adult smokers."
        }, 
        "brief_title": "A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Smoking", 
            "Vaccines"
        ], 
        "condition_browse": {
            "mesh_term": "Smoking"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Current cigarette smokers\n\n          -  Males or females of non-child bearing potential, who are between the minimum legal\n             age for smoking (approximately 18 or 19 years, depending on local jurisdiction) and\n             55 years, inclusive, and who are motivated to stop smoking.\n\n          -  Subjects must have smoked an average of at least 10 cigarettes per day during the\n             past year and during the month prior to the prescreening assessment for entry, with\n             no period of abstinence greater than 3 months in the past year.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, or neurologic disease that may\n             compromise their ability to safely participate in the study.\n\n          -  Active suicidal ideation or history of suicidal behaviors within the past 5 years\n             prior to the screening visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01672645", 
            "org_study_id": "B3771001"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-05402536", 
                "description": "Intramuscular, multiple dose", 
                "intervention_name": "NIC7-001", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "PF-06413367", 
                "description": "Intramuscular, multiple dose", 
                "intervention_name": "NIC7-003", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Saline (0.9% sodium chloride)", 
                "intervention_name": "Saline", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Smoking cessation", 
            "vaccine", 
            "Phase 1"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3771001&StudyName=A%20study%20to%20assess%20the%20safety%20and%20tolerability%20of%20different%20doses%20of%20PF-05402536%20and%20PF-06413367%20in%20healthy%20adult%20smokers."
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5V 2T3"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H4N 3C5"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sherbrooke", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J1H 1Z1"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Randomized, Double Blind, Placebo Controlled Study To Evaluate The Safety, Tolerability, Immunogenicity, And Exploratory Efficacy Of 4 Ascending Dose Levels Of Pf-05402536 And Pf-06413367 In Healthy Adult Smokers", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Frequency of solicited local reactions (erythema, induration, and pain) and severity of the local reactions as self-reported on electronic diaries (e-diaries) for 7 days following vaccination.", 
                "safety_issue": "Yes", 
                "time_frame": "Within 7 days after dose"
            }, 
            {
                "measure": "Frequency of solicited systemic events (fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, and new or worsening joint pain) and severity of solicited systemic events as self-reported on e-diaries for 7 days following vaccination.", 
                "safety_issue": "Yes", 
                "time_frame": "Within 7 days after dose"
            }, 
            {
                "measure": "Number of Participants With Unsolicited Treatment-Emergent Adverse Events (AEs) by Seriousness and Relationship to Treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 364"
            }, 
            {
                "measure": "Number of Participants With Abnormal Safety Laboratory Findings by Seriousness and Relationship to Treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 364"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01672645"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Antibody titers against nicotine.", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 364"
            }, 
            {
                "measure": "Avidity of antibodies against nicotine.", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 364"
            }, 
            {
                "measure": "7-day point prevalence of smoking abstinence", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 364"
            }, 
            {
                "measure": "4-week continuous abstinence rate from smoking", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 364"
            }, 
            {
                "measure": "smoking behavioral measurements (including Minnesota Nicotine Withdrawal Scale, Modified Cigarette Evaluation Questionnaire, and Brief Questionnaire of Smoking Urges)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 364"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}